Clinical Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: heart | prostate cancer | prostate | cardiovascular
Age: Between 18 - 90 Years
Other eligibility criteria:
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required